Nebraska’s Dedicated Theranostics CenterTheranostics = Therapy + Diagnostics Theranostics is a new field of medicine which combines specific targeted therapy based upon a specific targeted diagnostic test. With a key focus on patient centered care, theranostics provides a transition from conventional medicine to contemporary personalized and precision medicine. The NCS Theranostics Center offers comprehensive in-house services including:
|
The diagnostic component of theranostics determines and defines the type and extent of disease. This information allows decisions to be made on timing, quantity, type of drugs, and choice of treatment options, as well as helping to evaluate a patient’s response to treatment.
The development of the companion therapeutic component focuses on individualizing treatment by targeting therapy to the individual’s specific disease. Because the therapeutic agent is specifically targeted to sites of disease (with significantly reduced drug exposure to normal tissue), higher doses of the therapeutic agent may be safely administered.
NCS Difference
In addition to the benefits of targeted therapy over conventional chemotherapy, your care at Nebraska Cancer Specialists will truly be individualized to you and our dedicated theranostics care team will be your strongest advocate.
What sets Nebraska Cancer Specialists’ Theranostics Center apart?
- Personalized care team dedicated to you
- No delays in consultation or treatment
- Theranostics care team is part of your medical oncology care team
- Convenient and private outpatient setting
The NCS Theranostics team was recently honored by being featured on Siemens Healthineers website showing the journey of one of our patients, Glenda.
Read and Watch Here |
|
How Theranostics WorksTheranostics uses Peptide Receptor Radionuclide Therapy (PRRT) which is targeted radiation to kill cancer cells from within.The diagnostic component determines and defines the type and extent of the disease which allows decisions to be made on the timing, quantity, type of drugs, and choice of treatment options. The therapy component focuses on individualizing treatment by targeting therapy to an individual’s specific disease and administering the therapeutic agent to targeted sites of the disease which allows for higher doses administered safely to the site without significant exposure to normal tissue. |
Peptide Receptor Radionuclide Therapy (PRRT)
- A treatment that uses targeted radiation to kill cancer cells from within. It is a form of nuclear medicine.
- PRRT is comprised of a targeting molecule that binds to specific receptors (somatosta- tin) on the tumor cell surface and a radioactive particle that can kill the tumor cell.
- LUTATHERA® (lutetium Lu 177 dotatate) is the first FDA-approved PRRT.
- PRRT is comprised of a targeting molecule that binds to specific receptors (somatosta- tin) on the tumor cell surface and a radioactive particle that can kill the tumor cell.
- LUTATHERA® (lutetium Lu 177 dotatate) is the first FDA-approved PRRT.
- A treatment that uses targeted radiation to kill cancer cells from within. It is a form of nuclear medicine.
- LUTATHERA® (lutetium Lu 177 dotatate) is the first FDA-approved PRRT.
- A treatment that uses targeted radiation to kill cancer cells from within. It is a form of nuclear medicine.
- PRRT is comprised of a targeting molecule that binds to specific receptors (somatosta- tin) on the tumor cell surface and a radioactive particle that can kill the tumor cell.
- A treatment that uses targeted radiation to kill cancer cells from within. It is a form of nuclear medicine.
- PRRT is comprised of a targeting molecule that binds to specific receptors (somatosta- tin) on the tumor cell surface and a radioactive particle that can kill the tumor cell.
- PRRT is comprised of a targeting molecule that binds to specific receptors (somatosta- tin) on the tumor cell surface and a radioactive particle that can kill the tumor cell.
Educational Resources
-
What is Theranostics?
Siemens Healthineers video overview of Theranostics and how it impacts cancer treatment
Watch Video
-
-
-
Research Publication
by Dr. Mehr & Dr. HaukeMaximizing the Benefit
of Systemic Targeted Radiation Therapy in Metastatic
Castration‑Resistant Prostate CancerRead Here
Meet Our Theranostics TeamOur dedicated theranostics team is here to make your care as streamlined and smooth as possible. We strive to ensure you understand every stage of your treatment while making sure your care is efficient. |
Theranostics Team
Samuel Mehr MD |
Hadi Zahra MD, DABR |
Amir Zahra DO, DABR |
 Aaron Braun MDInterventional Radiologist |
Joel Michalski MD, PHD |
Ralph Hauke MD, FACP |
Nagendra Natarajan MD, MPH |
Stefano Tarantolo MD, FACP |
Scott Degenhardt |
Ashley Servais |
Marlene Bridwell |
Jacklyn Birkel RN |
Jennifer Clarke |
Jena Depue |
Josh Rathe |
Christina Gregg |
Matthew McDonald |
Doug Synek |
Hanna Kurz |
Not Pictured:
Subhash Paknikar, MD, Michael Petrocchi, Tricia Hosher–Medical Assistant, Robert Komstra–Nuclear Medicine Technologist, and Angela Leon–Research Lab Coordinator
See Our Full Medical Oncologist Team
Contact Us Now to Learn More
To learn more or inquire about Nebraska Cancer Specialists Dedicated Theranostics Center, give us a call at 402.334.4773 or fill out the form below.
Purpose • Innovation • Relationship • Excellence
© 2025 Nebraska Cancer Specialists • Privacy Policy • design by Chip Thompson
Meet DOT.
